KEIO RESEARCHERS INFORMATION SYSTEM

Message from the Faculty Member 【 Display / hide 】

Message from the Faculty Member 【 Display / hide 】

• 自分のこれまでの経験では、実験がうまくいってもそこから得られるものは何もありません。失敗して、原因をあれこれ考えることで自分が知らなかった知見を得たり、新しい発見をしたりします。したがって、多くのことに果敢にチェレンジしてたくさんの失敗を重ねて欲しいと思います。失敗が必ず皆さんの糧になります。

Other Disclosed Information 【 Display / hide 】

Other Disclosed Information 【 Display / hide 】

• Metabolomics, Analytical Chemistry

Career 【 Display / hide 】

Career 【 Display / hide 】

• 1984.04

  -

  1992.03

  Application Chemist, Yokogawa Corp.

• 1992.04

  -

  2001.03

  Yokogawa Analytical Systems Inc.

• 2001.04

  -

  2002.03

  University of the Ryukyus, Visiting Professor

• 2001.04

  -

  2005.03

  Faculty of Environmental Information/ Institute for Advanced Biosciences, Associate Professor

• 2003.07

  -

  2010.03

  Human Metabolome Technologies Inc., Director

display all >>

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 1980.04

  -

  1984.03

  Keio University, Faculty of Engineering, Applied Chemistry

  University, Graduated

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• Ph.D., Toyohashi University of Technology, Dissertation, 2000.03

Research Themes 【 Display / hide 】

Research Themes 【 Display / hide 】

• 枯草菌、大腸菌、酵母等のバクテリアからイネやマウスの組織、ヒトの血液、尿、赤血球、ガン細胞等のあらゆる生物種の細胞内全代謝物質（メタボローム）の測定法, 

  　

Books 【 Display / hide 】

Books 【 Display / hide 】

• Advances in Microscale Electro-and Liquid Phase-Based Separation Techniques

  El Rassi, Z., Ed. (Soga, T., contribution for Chapter Chapter 9), Elsevier Inc., 2026.03

  Scope: Chapter 9: “Capillary electrophoresis-mass spectrometry”,  Contact page： pp.279-294

  　View Summary

  Capillary electrophoresis-mass spectrometry (CE-MS) has gained a great deal of attention as a powerful tool for the analysis of charged compounds. This approach offers high-resolution, high-sensitivity, and wide versatility. Over the past three decades, several CE-MS methods have been developed and have made significant advances in analytical chemistry. In this chapter, the general strategies and principles of CE-MS methods will be discussed, including CE separation modes, interface techniques, mass spectrometry, new techniques to increase the throughput capability of CE-MS analysis, metabolomics, and even single-cell analysis, which has received much attention in recent years. Finally, general conclusions and perspectives are provided.

  • Access to Document (DOI)

• Amino Acid Analysis : Methods and Protocols

  Alterman M.Ed., (Hirayama, A., Ikeda, S., Sato, A., Soga, T., contribution for Chapter 23）, Humana Press, 2019.07

  Scope: Chapter 23: Amino Acid Analysis by Capillary Electrophoresis-Mass Spectrometry,  Contact page： 307-313

  　View Summary

  Capillary electrophoresis-mass spectrometry (CE-MS) has been developed as a powerful tool in the analysis of charged compounds. To simultaneously analyze free amino acids, an electrolyte with low pH was used to positively charge all of the amino acids. In this condition, all protonated amino acids migrated toward the cathode in CE and then were sensitively and selectively detected by MS. This method is simple, rapid, and selective and could readily be applied to the analysis of free amino acids in various samples. In this chapter, the detailed procedure to analyze amino acids using CE-tandem mass spectrometry (MS/MS) is described.

• Oceanography Challenges to Future Earth : Human and Natural Impacts on our Seas

  Komatsu, T., Ceccaldi, H-J., Yoshida, J., Prouzet, P., Henocque, Y. Ed., (Nakano, T., Shirakawa, H., Yeo, G., Devlin, R.H., Soga, T., contribution for Part IV ), Springer, 2019.02,  Page： 430

  Scope: Part IV Innovative Research: Metabolome profiling of growth hormone transgenic coho salmon by capillary electrophoresis time-of-flight mass spectrometry,  Contact page： 223-234

• Capillary Electrophoresis-Mass Spectrometry for Metabolomics

  Ramautar R. Ed., (Hirayama A, Soga T. contribution for CHAPTER 7), The Royal Society of Chemistry, 2018.07,  Page： 300

  Scope: CHAPTER 7: CE-MS for anionic and cationic metabolic profiling: system optimization and applications,  Contact page： 134-160

• ONCO-METABOLOMICS; A NEW CLUE TO UNDERSTAND CARCINOGENESIS, CANCER BIOLOGY AND TO DEVELOP NOVEL DIAGNOSTICS AND THERAPEUTICS

  Esmi, H., Mak, T.W., Soga, T., Suematsu, M.,Mori, M. Ed, Princess Takamatsu Cancer Research Fund, 2016.04

display all >>

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Elevated glucose metabolism via the hexosamine biosynthesis pathway: A metabolic signature of high-fluorodeoxyglucose-uptake lung adenocarcinoma

  Watanabe, H., Makinoshima, H., Kanauchi, N., Kabasawa, T., Suzuki, J., Takamori, S., Sasage, T., Abe, K., Hoshijima, K., Uchida, T., Soga, T., Shiono, S.

  Surg. Today 56 ( 8 ) 1645 - 1656 2026.08

  Joint Work, Accepted,  ISSN  09411291

  　View Summary

  Purpose
  To evaluate hexosamine biosynthetic pathway (HBP) involvement in high-fluorodeoxyglucose (FDG)-uptake lung adenocarcinoma.
  
  Methods
  We conducted metabolomic analysis to evaluate the HBP in patients with lung adenocarcinoma, who underwent preoperative 18-FDG positron emission tomography. Capillary electrophoresis-time-of-flight mass spectrometry was done to obtain 511 small-molecule metabolite spectra, and a principal component analysis was performed.
  
  Results
  We examined 80 tissue samples: 40 tumor-adjacent non-tumor tissue samples and 40 resected lung adenocarcinomas. The principal component analysis confirmed good clustering between the tumor and non-tumor tissues. The non-tumor tissues comprised uniform materials, whereas the tumor tissues comprised a mixture of materials. Heatmaps for 50 metabolites revealed lower glucose and citrate levels and higher levels of lactate, glycolysis metabolites, succinate, fumarate, adenosine di- and -monophosphate, and all essential amino acids in the tumor tissues than the non-tumor tissues. HBP intermediate and uridine diphosphate N-acetylglucosamine levels were also higher in the tumor tissues. Both lactate and HBP intermediate levels were higher in hypermetabolic tumor tissues (standardized uptake value ≥ 3) than in non-hypermetabolic tumor tissues (standardized uptake value < 3). Low-FDG-uptake cells showed strong expression for glucose transporter SLC2A1 and weak expression for O-linked N-acetylglucosamine, whereas high-FDG-uptake cells showed strong expression for both markers.
  
  Conclusions
  Hypermetabolic adenocarcinoma may be associated with intensified glycolysis and HBP activation.

  • Access to Document (DOI)

• Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small-Cell Lung Cancer Models

  Tsurumi, K., Nomura, M., Ouchi, M., Yagishita, S., Kikuchi, N., Sato, T., Morita, M., Yamashita, Y., Hayashi, K., Soga, T., Hamada, A., Fukuhara, T., Tanuma, N.

  Cancer Sci. online 2026.07

  Research paper (scientific journal), Accepted

  　View Summary

  Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. We previously showed that nicotinic acid riboside (NAR) sustains NAD biosynthesis in vivo and compensates for NAMPT inhibition in SCLC models. Here, we evaluated combining NAMPT inhibition with dietary nicotinic acid (NA) restriction to suppress NAR-dependent NAD biosynthesis. This combination showed enhanced antitumor activity consistent with synthetic lethality in SCLC CDX models and showed robust efficacy in PDX models, including those derived from chemotherapy-refractory tumors. In most CDX models examined, combination therapy showed greater antitumor activity than standard chemotherapy with cisplatin and etoposide. Although we did observe transient leukopenia, the treatment was otherwise better tolerated than chemotherapy, with less impact on body weight and platelet counts. These findings support NAD metabolism-targeted therapy as a promising strategy to treat SCLC.

  • Access to Document (DOI)

• Plasma metabolomic signatures of heterogeneous multimorbidity trajectories in ageing: a population-based cohort study

  Toki, R., Iba, C., Omoto, Y., Matsumoto, M., Iida, M., Edagawa, S., Harada, S., Hirata, A., Miyagawa, N., Miyake, A., Hirayama, A., Sugimoto, M., Sato, A., Amano, K., Soga, T., Arakawa, K., Takebayashi, T.

  Geroscience online 2026.07

  Joint Work, Accepted,  ISSN  25092715

  　View Summary

  Age-related disease burden accumulates heterogeneously from later midlife to older age, but the biology underlying these divergent trajectories is poorly understood. We analysed 7199 adults aged 40 years and over in the Tsuruoka Metabolomics Cohort Study, Japan, with baseline fasting plasma metabolomics (94 metabolites measured by capillary electrophoresis-mass spectrometry) and linked health insurance claims. Monthly cumulative Charlson Comorbidity Index scores were constructed from aligned cohort entry to 60 months to capture accumulation of newly documented Charlson conditions after follow-up start. K-means clustering identified six trajectories of claims-recorded disease burden, and ordinal logistic regression related metabolites to ordered trajectory severity with adjustment for demographic and lifestyle factors. Six trajectories ranged from minimal accumulation to rapid progression. Nineteen metabolites were associated with greater trajectory severity after false discovery rate correction. Glutamate showed the strongest positive association (odds ratio, 1.18 per standard deviation; 95% confidence interval, 1.12-1.24), whereas cysteine-glutathione disulfide showed the strongest inverse association (odds ratio, 0.89; 95% confidence interval, 0.86-0.93). Eighteen of these metabolites were also associated with time to first newly documented Charlson disease. Disease-specific analyses linked glutamate to diabetes with complications, mild liver disease, and cerebrovascular disease. Exploratory cluster-specific analyses identified hippurate as a distinctive marker of a late-acceleration trajectory. These findings implicate amino acid metabolism, redox balance, and microbiome-host interactions as candidate biological pathways underlying heterogeneous patterns of age-related disease accumulation, and warrant replication in independent cohorts. These signals may inform biomarker development for accelerated disease-burden accumulation.

  • Access to Document (DOI)

• Metabolic buffering restricts phenotype switching in melanoma

  Ramírez-Sánchez, A., Jociles-Ortega, M., García-Martínez, J.M., Torrens-Martínez, I., Martínez-Useros, J., Louphrasitthiphol, P., Sweeney, M.I., Morente-Carrasco, A., Ruiz-Reyes, S., Redondo-Díaz, N., Olmos-De Blas, T., Fernández-Aceñero, M.J., Rodriguez-López, J.N., Soga, T., White, R.M., Goding, C.R., Sanchez-Del-Campo, L., García-Jiménez, C., Chocarro-Calvo, A.

  EMBO J. online 2026.07

  Research paper (scientific journal), Accepted,  ISSN  02614189

  　View Summary

  The impact of the metabolic microenvironment on epigenetically plastic cancer cells underpins phenotypic heterogeneity, a major cause of metastasis and therapy resistance. Nutrient limitation is a key microenvironmental stress, and can cause cells to transition from proliferative to invasive phenotypes, however, whether cancer cells have the capacity to delay phenotype switching remains unknown. Here, using melanoma as a model, we reveal that the ability to buffer glucose availability by accumulating and mobilizing glycogen can determine cancer cell phenotypic transitions. While proliferating cells contain high levels of glycogen, invasive cells are marked by depleted glycogen stores. Accordingly, the inability to store and metabolize glycogen leads to phenotype instability and a switch from proliferation to invasion. The amount of stored glycogen inversely correlates with tissue invasion depth in primary melanomas, and reduced expression of the glycogen phosphorylases PYGB/L and phosphoglucomutase 1 (PGM1) is associated with worse patient survival. Together, we identify metabolic glucose buffering as a determinant of invasive phenotype transitions in skin cancer, suggesting similar paradigms in other cancer types.

  • Access to Document (DOI)

• 2,3-Pyridinedicarboxylate Is Associated with Shorter Recurrence-Free Survival in Patients with Hypopharyngeal Squamous Cell Carcinoma

  Takase, H., Fujisawa, T., Hayashi, R., Makinoshima, H., Suzuki, Y., Soga, T., Fujii, S.

  Pathobiology 93 ( 2 ) 72 - 86 2026.06

  Research paper (scientific journal), Joint Work, Accepted,  ISSN  10152008

  　View Summary

  Introduction: Metabolites are associated with the biology of cancer; however, no metabolites related to prognosis have been identified in head and neck cancer. This study aimed to identify metabolites associated with prognosis in patients with hypopharyngeal squamous cell carcinoma (HPSCC).
  
  Methods: Fifty-two patients who underwent surgery for HPSCC were included and randomly divided into test and validation cohorts of 26 patients each for further metabolome analysis using capillary electrophoresis/mass spectrometry on tumor and non-tumor tissues of the hypopharynx. Twenty-two patients who received adjuvant therapy after surgery were included. The receiver operating characteristic (ROC) and univariate and multivariate analyses were used to explore the relationship between recurrence-free survival (RFS), clinicopathological factors, and differentiated metabolites.
  
  Results: ROC analysis revealed six metabolites significantly associated with RFS in both cohorts, and multivariate analysis indicated that 2,3-pyridinedicarboxylate was a significantly independent poorer prognostic factor in the cohorts including patients with HPSCC without any adjuvant therapies (p = 0.017).
  
  Conclusion: 2,3-Pyridinedicarboxylate, involved in NAD+ metabolism and genomic stability, suggests the possibility of developing molecular-targeted drugs for the production of metabolites related to prognosis. This study identifies novel prognostic metabolites and their associated metabolic pathways in HPSCC, highlighting potential therapeutic targets for treatment.
  
  Keywords: 2,3-Pyridinedicarboxylate; Hypopharyngeal squamous cell carcinoma; Metabolites; Recurrence-free survival.

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• Development of risk prediction models for mild cognitive decline and frailty using metabolomics in a population-based cohort

  Soga, Tomoyoshi

  科学研究費補助金研究成果報告書 2022

• Identifying functional metabolites that decide cell fates of cancer stem cells

  Soga, Tomoyoshi

  科学研究費補助金研究成果報告書 2022

• Development of metabolome profiling method and application to cancer screening

  Soga, Tomoyoshi

  Keio SFC journal (慶應SFC学会)  22 ( 2 ) 320 - 330 2022

  ISSN  13472828

• Metabolome-wide metabolic profiling and non-communicable disease prevention in a population-based cohort study

  Soga, Tomoyoshi

  科学研究費補助金研究成果報告書 2018

• Metabolomics : a new approach to elucidating biosystems

  Soga, Tomoyoshi

  Keio SFC journal (慶應義塾大学湘南藤沢学会)  15 ( 1 ) 64 - 75 2015

  ISSN  13472828

display all >>

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• メタボロームデータの取得

  Soga, T.

  Experimental Medicine (YODOSHA)     86 - 94 2025.03

  Article, review, commentary, editorial, etc. (other), Single Work

• タボローム測手技術の開発と生命科学における意義

  Soga, T.

  SEIKAGAKU (The Japanese Biochemical Society)  96 ( 2 ) 222 - 231 2024.04

  Article, review, commentary, editorial, etc. (other), Single Work

• マルチオミクスによる大腸がんの代謝解析 100年来のがん代謝の謎を解明

  Soga, T.

  CHEMISTRY & CHEMICAL INDUSTRY (The Chemical Society Of Japan)  77 ( 4 ) 268 - 270 2024.04

  Article, review, commentary, editorial, etc. (other), Single Work

• メタボローム解析からマルチオミクスへの展開―マルチオミクスによるがん代謝解析

  Soga, T.

  Experimental Medicine (YODOSHA)  41 ( 15 ) 59(2399) - 67(2407) 2023.09

  Article, review, commentary, editorial, etc. (other), Single Work

• 腫瘍における分岐鎖アミノ酸トランスポーターの役割

  Saito, Y., Soga, T.

  Experimental Medicine (YODOSHA)  40 ( 14 ) 2239 - 2244 2022.08

  Article, review, commentary, editorial, etc. (other), Joint Work

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• Development of CE-MS Metabolomics and Its Application in Cancer

  Tomoyoshi Soga

  [International presentation]  AOMS2025, The 10th Asia-Oceania Mass Spectrometry Conference (ANA InterContinental, Ishigaki island, Okinawa) , 

  2025.06

  , 

  Oral presentation (invited, special), he Mass Spectrometry Society of Japan

• Development of CE-MS Metabolomics and its Application in Cancer

  Tomoyoshi Soga

  [International presentation]  Metabolomics2024, 20th Annual Confereence of the Metabolomics Society (Osaka) , 

  2024.06

• Multi Omics analysis of colorectal cancer metabolism

  [International presentation]  2018 International Meeting on 22nd MDO and 33rd JSSX (Ishikawa Ongakudo, Kanazawa, Ishikawa) , 

  2018.10

  , 

  Oral presentation (invited, special), JSSX (The Japanese Society for the Study of Xenobiotics)、MDO(Microsomes and Drug Oxidations)

• Malti-omics reveals MYC as a master regulator of colorectal cancer metabolism

  SOGA TOMOYOSHI

  [International presentation]  The 1st International Symposium for Trans-Omics (Koshiba Hall, The University of Tokyo, Hongo Campus) , 

  2017.11

  , 

  Oral presentation (invited, special)

• Onco-metabolites and cancer specific metabolic pathways

  SOGA TOMOYOSHI

  [International presentation]  American Association for Cancer Research Annual Meeting 2017, AACR2017, 

  2017.04

  , 

  Oral presentation (invited, special)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• Study of therapeutic approaches to SUCLA2-deleted cancers

  2024.05

  -

  2026.03

  Japan Agency for Medical Research and Development(AMED), Project for Promotion of Cancer Research and Therapeutic Evolution（P-PROMOTE）, Takahashi, Chiaki, Commissioned ｒesearch, Coinvestigator(s)

• Transomic analysis of hybernation and torpor Planned Research

  2023.06

  -

  2026.03

  Ministry of Education,Culture,Sports,Science and Technology(MEXT)/Japan Society for the Promotion of Science(JSPS) , Grant-in-Aid for Transformative Research Areas (A), Kuroda, Shinya, Research grant, Coinvestigator(s)

• 大腸がんにおけるオンコメタボライト・L-2HGの分子基盤の解明

  2022.06

  -

  2025.03

  Ministry of Education,Culture,Sports,Science and Technology(MEXT)/Japan Society for the Promotion of Science(JSPS) , Grant-in-Aid for Scientific Research (C), Tabata, Sho, Other, Coinvestigator(s)

• Spatio-temporal trans-omics analysis of metabolic control mechanisms of multi-cellular organ systems

  2021.10

  -

  2026.03

  Japan Science and Technology Agency(JST), Strategic Basic Research Programs CREST, Kuroda, Shinya, Commissioned ｒesearch, Coinvestigator(s)

• Development of novel therapy targeting SUCLA2 deficiency in advanced prostate cancer

  2021.05

  -

  2023.03

  Japan Agency for Medical Research and Development(AMED), Project for Cancer Research and Therapeutic Evolution (P-CREATE) , Takahashi, C., Commissioned ｒesearch, Coinvestigator(s)

display all >>

Works 【 Display / hide 】

Works 【 Display / hide 】

• 経済産業省主催「バイオ人材育成事業」メタボローム実習講師

  SOGA TOMOYOSHI

  2004.12

  , 

  Other, Joint

• 日経BP社主催バイオファイナンスギルド　メタボローム講座

  SOGA TOMOYOSHI

  2004.08

  , 

  Other, Joint

• キャピラリー電気泳動による無機陰イオン、有機酸、アミノ酸の分析

  そがともよし

  2001.10

  -

  Present

  , 

  Other

  　View Details

  キャピラリー電気泳動法の装置、測定法の原理および様々な測定例を解説した

Intellectual Property Rights, etc. 【 Display / hide 】

Intellectual Property Rights, etc. 【 Display / hide 】

• カテコールアミン類の分析方法(Apparatus and Method for Catecholamine Analysis)

  Date applied： 特願平01-272206  1989.10 

  Date announced： 特開平03-134561  1991.06 

  Date issued： 特許第2833058号  1998.10

  Patent, Single

• 陰イオン性化合物の分析方法(Apparatus and Method for Anion Analysis)

  Date applied： 特願平08-143048  1996.06 

  Date announced： 特開平09-325130  1997.12 

  Date issued： 特許第2912232号  1999.04

  Patent, Single

• キャピラリー電気泳動による陰イオン、アミノ酸、糖類の分析方法及び装置(Capillary Electrophoresis Apparatus and Method for Anions, Amino Acids and Carbohydrate Analysis)

  Date applied： 特願平10-145244  1998.05 

  Date announced： 特開平11-337524  1999.12 

  Date issued： 特許第3038184号  2000.02

  Patent, Single

• 陰イオン性化合物の分離分析方法及び装置(Apparatus and Method for Anion Analysis)

  Date applied： 特願2001-224341  2001.07 

  Date announced： 特開2003-035698  2003.02 

  Date issued： 特許第3341765号  2002.08

  Patent, Single

• 電気泳動測定によるイオン性化合物の移動時間予想方法

  Date applied： 特願2004-245728  2004.08 

  Date announced： 特開2006-064472  2006.03 

  Date issued： 特許第3871689号  2006.10

  Patent, Joint

display all >>

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• Fukuzawa Award

  Soga, T., 2022.11, Keio Univ., メタボローム（細胞内全代謝物質）解析技術の開発と実用化

  Type of Award： Keio commendation etc.

• The 2nd Shigeru Terabe Award

  2015.11,  Division of Electrophoresis, Japan Society for Analytical Chemistry, CE-MSメタボローム測定技術の開発と実用化

  Type of Award： Award from Japanese society, conference, symposium, etc.

• Keio Award

  SOGA Tomoyoshi, 2011.11, Keio University, CE-MSメタボローム測定技術の開発と実用化

  Type of Award： Keio commendation etc.

• 第7回酸化ストレスと肝研究会　奨励賞

  SOGA Tomoyoshi, 2010.11, 酸化ストレスと肝研究会, メタボロミクスによる新規酸化ストレスマーカーの同定と肝臓疾患スクリーニング

  Type of Award： Award from Japanese society, conference, symposium, etc.

  　View Description

  第7回酸化ストレスと肝研究会における研究発表による

• The prize of the chairman of HATSUMEI KYOKAI

  SOGA Tomoyoshi, 2009.07, Japan Institute of Invention and Innovation, Apparatus and Method for Metabolome Analysis

  Type of Award： Other

display all >>

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• SEMINAR B

  2024

• METABOLOMICS

  2024

• METABOLOME ANALYSIS LABORATORY PRACTICE

  2024

• MASTER SEMINAR

  2024

• INDEPENDENT RESEARCH

  2024

display all >>